Advertisement
U.S. markets close in 3 hours 56 minutes

Oncolytics Biotech Inc. (ONCY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0500+0.0200 (+1.94%)
As of 11:49AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close1.0300
Open1.0400
Bid0.7488 x 100
Ask1.0800 x 100
Day's Range1.0100 - 1.0500
52 Week Range0.8800 - 3.3900
Volume137,900
Avg. Volume401,760
Market Cap79.191M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-0.3000
Earnings DateMay 03, 2024 - May 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ONCY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Oncolytics Biotech Inc.
    Technical Assessment: Neutral in the Intermediate-TermWas that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.
    Rating
    Fair Value
    Economic Moat
    5 hours agoArgus Research
View more
  • Insider Monkey

    Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

    Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript March 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Oncolytics Biotech’s Fourth Quarter and Full Year 2023 Conference Call. All participants […]

  • CNW Group

    Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

    Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

  • Newsfile

    Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

    Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.Read the full article on Investoorideas.com Research Nester says, "The global pancreatic cancer market size is slated to expand at ~